作者
Alberta Y Hoi, Magdy N Iskander, Eric F Morand
发表日期
2007/9/1
来源
Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued)
卷号
6
期号
3
页码范围
183-190
出版商
Bentham Science Publishers
简介
Macrophage migration inhibitory factor (MIF), a cytokine originally reported in the 1960s as the prototypic T lymphokine, has emerged in recent years as a key factor regulating inflammatory responses. Both by directly activating immune cells, and by participating in activation entrained by other stimuli, MIF is important in innate and adaptive immune responses as well as tissue-specific mechanisms of damage. As a consequence of its involvement in multiple stages of the immune-inflammatory response, MIF has the potential to be involved in the pathogenesis of a range of immunemediated inflammatory diseases affecting multiple organ systems. Diseases in which a role for MIF has been strongly validated include rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, atherosclerosis, asthma, inflammatory liver disease, and most recently systemic lupus erythematosus. Recent data have provided …
引用总数
200820092010201120122013201420152016201720182019202020212022202320241011991114107765586432
学术搜索中的文章
AY Hoi, MN Iskander, EF Morand - Inflammation & Allergy-Drug Targets (Formerly Current …, 2007